FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment

U.S. FDA — FDA today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.

Read the original at U.S. FDA ↗

Auto-published by the finit.news Events monitor from U.S. FDA; summarized by AI and may contain errors — verify against the primary source. October 20, 2026.

By